

RESEARCH

Open Access

Genital herpes evaluation by quantitative TaqMan PCR: correlating single detection and quantity of HSV-2 DNA in cervicovaginal lavage fluids with cross-sectional and longitudinal clinical data

Bulbulgul Aumakhan^{1*}, Andrew Hardick², Thomas C Quinn^{2,3}, Oliver Laeyendecker^{2,3}, Stephen J Gange¹, Chris Beyrer¹, Christopher Cox¹, Kathryn Anastos⁴, Mardge Cohen⁵, Ruth M Greenblatt⁶, Daniel J Merenstein⁷, Howard Minkoff⁸, Marek Nowicki⁹, Charlotte A Gaydos²

Abstract

Objective: To evaluate the utility of a single quantitative PCR (qPCR) measurement of HSV (HSV-1&2) DNA in cervicovaginal lavage (CVL) specimens collected from women with predominantly chronic HSV-2 infection in assessing genital HSV shedding and the clinical course of genital herpes (GH) within a cohort with semiannual schedule of follow up and collection of specimens.

Methods: Two previously described methods used for detection of HSV DNA in mucocutaneous swab samples were adapted for quantification of HSV DNA in CVLs. Single CVL specimens from 509 women were tested. Presence and quantity of CVL HSV DNA were explored in relation to observed cross-sectional and longitudinal clinical data.

Results: The PCR assay was sensitive and reproducible with a limit of quantification of ~50 copies per milliliter of CVL. Overall, 7% of the samples were positive for HSV-2 DNA with median \log_{10} HSV-2 DNA copy number of 3.9 (IQR: 2.6-5.7). No HSV-1 was detected. Presence and quantity of HSV-2 DNA in CVL directly correlated with the clinical signs and symptoms of presence of active symptomatic disease with frequent recurrences.

Conclusion: Single qPCR measurement of HSV DNA in CVL fluids of women with chronic HSV-2 infection provided useful information for assessing GH in the setting of infrequent sampling of specimens. Observed positive correlation of the presence and quantity of HSV-2 DNA with the presence of active and more severe course of HSV-2 infection may have clinical significance in the evaluation and management of HSV-2 infected patients.

Introduction

Genital herpes (GH) is a common chronic sexually transmitted infection worldwide with substantial morbidity [1,2] caused mainly by Herpes Simplex Virus Type 2 (HSV-2) and sometimes by HSV-1. Women, in particular, are disproportionately affected. GH is also commonly found among Human Immunodeficiency Virus (HIV) infected individuals in whom it is associated with increased HIV replication [3,4].

The majority of HSV-2 infected individuals is 'asymptomatic' or unaware of infection [5,6]. Those with symptomatic HSV-2 can experience recurrent episodes of genital lesions that appear to diminish in severity and frequency over time [7-9]. Most individuals with chronic HSV-2 have mild or asymptomatic infection.

Cell culture isolation of HSV is the preferred diagnostic test, usually used in conjunction with symptomatic primary or first clinical episode. However, its sensitivity for recurrent or healing lesions is low. More recently, PCR-based methods have been actively investigated for the detection of HSV DNA in mucocutaneous lesions and have shown to be superior to viral culture [10-12].

* Correspondence: an_bulbul@yahoo.com

¹Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
Full list of author information is available at the end of the article

PCR has also been shown to be more sensitive in detecting asymptomatic shedding or shedding episodes in the absence of clinically obvious lesions [13-16]. Nevertheless, the potential utility of broad based application of PCR based techniques in the evaluation and management of HSV-2 infected patients, especially of those with longstanding and/or asymptomatic GH, is less clear given the plausibility of reduced genital shedding over time. In addition, the essential goal of most PCR assays was detection, i.e. determining the presence or absence of HSV target nucleic acid sequences in the sample. However, for pathogenesis studies and clinical management purposes, including prognosis or determining optimal drug regimens, quantification of actual viral load may be useful. Data on the usefulness of quantification of HSV DNA in genital secretions, perhaps due to mild nature of most HSV-2 infections, is limited and restricted mainly to evaluating clinical and virologic efficacy of antiviral compounds and defining the threshold of HSV infectivity as a potential factor in the transmissibility of infection [17-22]. Nevertheless, available evidence suggests that HSV-2 viral titer in genital secretions can be a useful means for disease monitoring purposes. A study by Filen et al., for example, found that first episodes of GH were associated with significantly higher viral loads compared to recurrent or atypical cases [9]. Yet, other studies doubt the usefulness of monitoring HSV loads in clinical samples [21,23]. Some of the challenges in ascertaining these issues are related to intermittent nature and wide variability in the frequency and amount of HSV shedding observed among infected individuals. Many investigators use repeated and frequent sampling up to multiple times a day to overcome these challenges [24]. However, for practical reasons, not all research and clinical settings can easily implement such an approach and, hence, the clinical usefulness of quantitative PCR (qPCR) methods, especially for those with established chronic GH and in the setting of infrequent sampling of specimens, is unclear.

Therefore, using quantitative PCR technique, we aimed to explore the usefulness of assessing genital HSV infection by single qPCR measurement of HSV DNA in cervicovaginal lavage (CVL) specimens of women with mostly longstanding HSV-2 infection within the setting of a research cohort with semiannual scheduling of follow up and specimen sampling. The presence and quantity of CVL HSV DNA were explored in relation to observed cross-sectional and longitudinal clinical data.

Methods

Study population and specimens

The study population consisted of HIV infected and uninfected participants of Women's Interagency HIV Study (WIHS), a multicenter cohort study of HIV in

women across six sites in the US (Los Angeles, CA; Washington, DC; San Francisco, CA; New York City/Bronx, NY; Brooklyn, NY; and Chicago, IL). WIHS enrolled 2059 HIV infected and 569 high risk HIV uninfected women between October 1994 and November 1995 [25]. At enrollment, over 90% of WIHS participants were seropositive for HSV-1 and more than 80% of HIV infected women seropositive for HSV-2. HSV serostatus was determined by HSV type specific antibodies by glycoprotein G-based enzyme immunoassay (gG-EIA, Gull Laboratories, Salt Lake City, Utah). Negative and equivocal results were confirmed by Western Blot [26]. Gynecological examination included assessment for genital tract infections and genital tract dysplasia as previously described [27]. Self-reports of GH sores and observations of presence of lesions, sites of the lesions and whether the lesions were observed at multiple (three or more) locations were collected at each study visit. CVL specimens were collected by flushing the cervix with 10 ml sterile normal saline aspirated from the posterior vaginal fornix. The specimens were then transported to the processing laboratory on ice within 24-26 hours and 1 ml aliquots were stored at a central repository at -70°C. Whole unspun and unfractionated CVL was used for this study.

Total of 509 single CVL samples from 509 women were retrieved from repository for testing. Ten samples each from dual positive (HIV+/HSV+), HIV only (HIV+/HSV-), HSV only (HIV-/HSV+) positive women and 40 samples from dual negative (HIV-/HSV-) women were retrieved from the baseline visit to use in the assay validation. The rest were selected based on the following criteria: 1) had known baseline HSV serology status; 2) had information on self reported history of GH sores, physical and gynecological exams; 3) had at least one follow-up visit since the baseline; and 4) had sufficient volume of more than 5 ml CVL available to preserve the specimens. To assess the correlation of the initial or 'baseline' CVL HSV DNA titer with the number of subsequent lesion recurrences, we identified eligible samples from women who had multiple (> 1) recurrent episodes of lesion outbreaks (referred thereafter as lesion-episode) observed during the follow up. For these women, CVL sample from the earliest available lesion-episode was retrieved for testing and considered as a 'baseline' episode. Since the earliest available lesion-episode is different for each woman, the visits from which samples were pulled ranged from 1 to 24 with the median visit number of 3 (IQR: 1-8).

Extraction of HSV DNA

CVL fluids were thawed at room temperature. DNA was extracted by QIAamp DNA blood minikit from 200 µl of whole CVL (Qiagen, Valencia, California) using the

Blood and Body Fluid Spin Protocol. The DNA was eluted into 55 μ l of Qiagen AE buffer. Each extraction included positive control HSV isolates (HSV-1 strain GHSV-UL46 and HSV-2 strain MS, ATCC, Manassas, VA) and RNase- and DNase-free water as the negative control.

Preparation of HSV DNA standards

Ten-fold serial dilutions were prepared with commercial HSV-1&2 quantified DNA (ABI Advanced Technologies, Inc., Columbia, Maryland) to generate a standard curve. The DNA stocks were serially diluted with RNase- and DNase- free water and/or with CVL fluids pooled from HIV (+) and HIV (-) women whose CVLs were negative for HSV-1&2 DNA. To avoid repeated freeze-thaw of the DNA stock which could negatively affect the reproducibility of the assay, single use panels of serial dilutions were prepared immediately upon receipt of the DNA stock and stored at -20°C until further use. Standards were analyzed in duplicates and used to generate a standard curve as well as a positive control for each PCR run.

Primers, probes and target sequence for amplification

Primers were adapted from two different sources. The forward primer (GbTypF: 5'-CGC ATC AAG ACC ACC TCC TC-3') was as described by Corey L. et al. [28]. The reverse primer (HSV1&2-R: 5'-AGC TTG CGG GCC TCG TT-3') and probes (HSV1-probe: 5'-CGG CCC AAC ATA TCG TTG ACA TGG C-3' and HSV2-probe: 5'-CGC CCC AGC ATG TCG TTC ACG T-3') were as described by Namvar et al. [29]. The probe region differs by 5 nucleotides and was previously shown to differentiate between HSV-1 and HSV-2 without cross-reactivity [29]. Probes were labeled at the 5'-end with FAM or VIC and at the 3'-end with TAMRA. Primers allowed amplification of a highly specific 155-nucleotide region of gB envelope gene homologous for HSV-1&2 which represented the summed extension of overlapping target sequences used by the two groups.

TaqMan PCR

The final 50 μ l PCR reaction mix contained 25 μ l of 2 \times TaqMan universal master mix (PE Applied Biosystems, Foster City, CA), 900 nM of each primer, 100 nM of each probe and 10 μ l of sample DNA. PCR was performed using an ABI 7900 HT sequence detection system (PE Applied Biosystems, Foster City, CA) with the following cycling conditions: incubation for 2 min at 50°C (uracil-*N*-glycosylase digestion) and denaturation at 95°C for 10 min followed by 45 cycles of 15 s denaturation at 95°C and 60 s annealing/extension at 58°C. Specimens were blinded to clinical information and run in duplicate. A sample was considered positive if the

detected quantity was above or equal to assay limit of quantification in both replicates.

Statistical analysis

Assay performance was evaluated using within and between assay measures of efficiency (slope of standard curve), linearity (R-square) and reproducibility (mean threshold (Ct) values, standard deviation (SD) and coefficient of variation (CV)) from standard curve data. Limit of detection (LoD) and limit of quantification (LoQ) were estimated using the delta method to approximate the relative precision of the estimated concentration as previously described [30]. Values of HSV-2 DNA were log₁₀ transformed for analyses. Proportions with detectable HSV DNA by clinical markers of genital HSV infection were compared using chi-square and median quantities by Wilcoxon rank-sum tests. The markers were HSV-2 seropositivity, self report of GH lesions, the presence of any lesions and/or lesions clinically suspected as herpetic. To assess whether there is any relationship between the initial 'baseline' HSV-2 viral load and subsequent clinical course of GH, the correlation between the CVL HSV-2 DNA titer and the total number of lesion-recurrences observed during the subsequent follow up was explored. Duration of subsequent follow up was determined by the total number of follow up visits observed since the detection of HSV DNA in CVL. Ratio of frequency of subsequent lesion-episodes on duration of follow up was used to account for varying lengths of follow up among women. Pearson's *r* or Spearman's rho were used to estimate the correlations of interest. P-values of < 0.1 were considered significant. Statistical analyses were carried out using STATA 10.1 software (STATA Corporation, College Station, Texas). Graphs were created using GraphPad Prism Software, v. 5.03 (GraphPad Software, La Jolla, California).

Results

Assay performance

For HSV-1, the Ct values ranged from 21.62 for log₁₀5 to 35.68 for log₁₀1 with an average slope of -3.22 (range: -3.17 to -3.27). For HSV-2, the corresponding Ct values ranged from 23.74 to 38.50 with average slope of -3.33 (range: -3.23 to -3.49) indicating high efficiencies for both HSV types. The intra-assay CV (Ct) values for five dilutions of HSV-1&2 ranged from 0.02% to 4.26%. The inter-assay CV (Ct) ranged from 0.1% to 1.3%. R-square values for all runs were \geq 0.99. Standards were stable with consistent Ct values for all concentrations in multiple runs performed over the course of 6 months. No significant differences were observed in Ct values between water and CVL diluted standards (\leq 1-2 Ct difference). HIV status did not influence the test performance. Data for HSV-2 are shown in Table 1.

Table 1 Assay Reproducibility (HSV-2)

# copies per assay	Run	Ct ₁	Ct ₂	Intra-assay			Inter-assay		
				mean Ct	Ct SD	CV (Ct)	mean Ct	Ct SD	CV (Ct)
150,000	1	24.11	23.99	24.05	0.08	0.34	24.05	0.11	0.46
	2	24.18	24.13	24.15	0.04	0.15			
	3	24.12	23.74	23.93	0.27	1.13			
15,000	1	27.34	27.28	27.31	0.04	0.14	27.25	0.16	0.57
	2	27.46	27.25	27.36	0.15	0.55			
	3	26.97	27.16	27.07	0.13	0.50			
1,500	1	30.67	30.56	30.62	0.08	0.25	30.76	0.14	0.45
	2	30.97	30.81	30.89	0.12	0.38			
	3	30.81	30.74	30.77	0.05	0.16			
150	1	34.82	33.90	34.36	0.66	1.91	34.30	0.25	0.74
	2	34.50	34.52	34.51	0.01	0.03			
	3	34.09	33.94	34.02	0.10	0.31			
15	1	37.09	37.44	37.27	0.25	0.67	37.41	0.15	0.41
	2	37.83	37.32	37.57	0.36	0.96			
	3	38.50	36.25	37.38	1.59	4.26			

Limit of detection and limit of quantification

One to 1.5 copies per reaction were detected 50% of the time and 10 copies were detected in 100% of the runs. Thus, the LoD was considered as 1-2 copies/assay or 20-40 copies/ml. The LoQ for HSV-2 was ~2.3 copies per reaction corresponding to ~47 copies per mL of CVL and the LoQ for HSV-1 was ~6.4 copies per reaction or ~127 copies per mL of CVL. The higher LoQ observed for HSV-1 was due to slightly lower precision of the estimates in the linear regression compared to HSV-2. At least 6 replicates for each concentration from multiple runs were used to estimate LoQ.

Study population

The study population consisted of 379 (74%) dually infected (HIV+/HSV+), 22 (4%) HIV only (HIV+/HSV-), 68 (13%) HSV only (HIV-/HSV+) and 40 (8%) neither HIV nor HSV (HIV-/HSV-) infected individuals (Table 2). Median baseline age of women was 35 years. HSV seropositive women were predominantly African American and significantly older as opposed to seronegative women. Intravenous drug use and heterosexual risk were the commonly identified routes of HIV exposure among HSV seropositive women. Median follow up of women was 24 visits (IQR: 14-24).

HSV-2 DNA detection by HIV/HSV status

Overall, 35 (7%) individuals were positive for genital HSV-2 DNA with a median log₁₀ DNA copy number of 3.9 (IQR: 2.6 - 5.7). No HSV-1 was detected. Log

transformed values of HSV-2 DNA were normally distributed (Shapiro-Wilk normality test $p = 0.406$). By HIV/HSV status, HIV+/HSV+ group had 27 women with detectable HSV-2 DNA ($n = 379$, 7%, median log₁₀ HSV-2 DNA = 4.4, IQR: 2.6-5.9), HIV-/HSV+ group - 4 ($n = 68$, 6%, median log₁₀ HSV-2 DNA = 2.8, IQR: 2.1-4.0) and HIV-/HSV- group - 4 women positive for HSV-2 DNA ($n = 40$, 10%, median log₁₀ HSV-2 DNA = 3.7, IQR: 3.4-5.2). The number of HIV+/HSV- women was small ($n = 22$) and none had detectable HSV-2 DNA.

HSV-2 DNA detection by clinical markers GH infection

Detection was highest for lesions clinically suspected as herpetic, 27% ($p < 0.001$) and 8% for presence of any lesions (Table 3). About 6% of those with lesions not identified as herpetic were positive for CVL HSV-2 DNA.

'Baseline' CVL HSV-2 viral load and subsequent clinical course

Positive correlation was observed between the CVL HSV-2 DNA load and the frequency of lesion-episodes observed during the subsequent follow up (Pearson $r = 0.48$, $p = 0.005$, Figure 1). Strength of the correlation did not change when the ratio of lesion-episodes frequency on the duration of follow up was used to account for varying lengths of follow up (Pearson $r = 0.50$, $p = 0.004$, Figure 2). There was also no correlation between the length of subsequent follow up and

Table 2 Demographic and risk characteristics of the 509 women by HIV/HSV serostatus

Definition	HIV+/HSV+ N = 379 (74%)	HIV+/HSV- N = 22 (4%)	HIV-/HSV+ N= 68 (13%)	HIV-/HSV- N = 40 (8%)
Median age at baseline, years (IQR)	38 (33-42)	36 (28-40)	34 (28-40)	26(22-30)
Race n (%)				
African American	225 (59%)	6 (27%)	45 (66%)	13 (33%)
Hispanic	79 (21%)	3 (14%)	15 (22%)	7 (18%)
White	55 (15%)	11 (50%)	6 (9%)	18 (45%)
Other	20 (5%)	2 (9%)	2 (3%)	2 (5%)
Risk exposure				
Intravenous drug use	135 (36%)	6 (27%)	16 (24%)	8 (20%)
Heterosexual risk	149 (39%)	12 (55%)	11 (16%)	10 (25%)
Transfusion risk	10 (3%)	0 (0%)	1 (1%)	1 (3%)
No identified risk	85(22%)	4 (18%)	40 (59%)	21 (53%)
Lifetime # of sex partners				
0-1	16 (4%)	1 (5%)	3 (4%)	1 (3%)
2-4	51 (13%)	5 (23%)	13 (19%)	6 (15%)
5-9	81 (21%)	8 (36%)	19 (28%)	10 (25%)
10-50	122 (32%)	6 (27%)	19 (28%)	21 (53%)
> 50	108 (28%)	2 (9%)	14 (21%)	2 (5%)
missing	1 (0.3%)	-	-	-

quantity of HSV-2 DNA (Spearman's rho = - 0.003, p = 0.852). Although there were no differences in the detection status, quantitatively, women with positive history of GH sores and lesions identified at three or more locations tended to have higher median quantities of HSV-2 DNA that were statistically significant at alpha level of 0.1 (Figure 3). Women with clinically suspected herpetic lesions had slightly higher median HSV-2 DNA titer but the difference did not reach statistical significance of p < 0.1. No quantitative differences by other markers were observed.

Table 3 CVL HSV-2 DNA detection by markers of genital herpes

Definition	Status (+/-) ^a	HSV-2 DNA (+), n/N (%)	p-value
HSV-2 serostatus	+	28/356 (8%)	0.251
	-	7/153 (5%)	
Self report of GH sores	+	4/42 (10%)	0.518
	-	31/467 (7%)	
Any lesions ^b	+	30/394 (8%)	0.296
	-	5/114 (4%)	
Herpetic lesions ^c	+	7/26 (27%)	0.001
	-	28/481 (6%)	

^a (+) condition present; (-) condition absent

^b any genital lesions vs. no any lesions

^c lesions clinically suspected as herpetic vs. no lesions or lesions not suspected as herpetic

HIV and HSV detection

Detailed analysis of the association between HIV and HSV detection including multivariate regression was described elsewhere (Aumakhan B, Gange SJ, Beyrer C, Gaydos CA, Minkoff H, Merenstein DJ, Cohen M, Anastos K, Greenblatt RM, Nowicki M, Quinn TC: Quantitative and qualitative correlates of cervicovaginal HSV-2 shedding among HIV infected women in Women's





Figure 1 Correlation between the frequency of subsequent lesion-episodes and CVL HSV-2 DNA titer, Pearson r = 0.48, p = 0.005.



Interagency HIV Study, submitted). Briefly, trend for reduced detection of HSV-2 DNA with higher CD⁺ T cell counts was observed (p -value for trend = 0.08). No significant associations were observed with HIV viral load and use of antiretroviral therapy.

Discussion


We explored the correlation of the presence and quantity of HSV-2 DNA in cervicovaginal fluids collected from women with predominantly established genital herpes infection with clinical manifestations observed at the visit (cross-sectionally) and over the course of follow up (longitudinally) using real time PCR technique. The

PCR assay adapted two previously reported methods [28,29] used for detection and typing of HSV DNA in mucocutaneous swab samples to quantification of HSV DNA in CVL samples. The combination of primers and probes from two different sources was a result of preliminary review of primers and probes from reported methods during which it was determined that the target sequences of these two methods overlapped resulting in a final amplicon of 155-nucleotide region of glycoprotein B gene highly specific for HSV-1 and HSV-2 differentiation. Two type specific forward primers used by Namvar et al. [29] were conveniently replaced by one common type primer described by Corey et al. [28] and the assay was implemented using the absolute quantification guidelines recommended by the manufacturer (ABI 7900 HT SDS, PE Applied Biosystems, Foster City, CA).

Overall, we found a 7% HSV-2 DNA detection rate in the tested samples. Despite testing for HSV-1, no HSV-1 DNA was detected. Herpetic lesions had the most correlation with the probability of detectable HSV-2 DNA in CVL with 27% positivity rate. Although this finding may not be surprising, the main point of this observation is the extent of this correlation in this particular population and what to expect if broader categories, such as presence of any lesions, are used. The latter was associated with 8% positivity rate.

Four HIV-/HSV- women tested positive for HSV-2 DNA in CVL suggesting that they may have had primary genital HSV-2 infection. Three of them had multiple lesion-episodes observed during the subsequent follow up. However, only one had active lesion at the time of sampling and one reported positive history of genital sores in the past 6 months. The individual with the active lesion had the highest viral load with log₁₀ HSV-2 DNA copy number of 6.4. Follow up measurement of serum anti-HSV-2 Ig G will be needed to confirm any subsequent seroconversion.

An interesting finding is the significant correlation observed between the 'baseline' CVL HSV-2 DNA load and the frequency of subsequent lesion recurrences observed during the follow up, which suggests that high HSV-2 load could be associated with frequent reactivations. Absence of the correlation between the length of subsequent follow up and HSV-2 DNA titer suggests that this association was not due to varying lengths of follow up. Trend towards higher median HSV-2 DNA titer with the presence of lesions at multiple locations could indicate that HSV-2 viral load plays a role in the severity of GH clinical expression. Although only 10% of women with self reported positive history of GH sores had detectable HSV-2 DNA, they tended to have higher HSV-2 DNA copy numbers compared to women without such history, which suggests that more readily recognizable lesions may harbor high levels of infectious virus.



Additional studies with a larger number of positive end-points will be needed to validate these results. Nevertheless, findings of this study were the basis for classifying HSV-2 infected women into groups of gradient degree of GH clinical activity (determined by the presence/absence of active symptomatic disease with multiple recurrences) in another study by our group, in which we observed direct dose dependent association between classic markers of HIV disease progression (CD4+ T cell count, HIV RNA load) and a degree of HSV-2 clinical activity, which lends additional support to these results [31].

Our 7% of HSV-2 DNA detection rate in CVL may seem low compared to some other reports that measured genital HSV shedding using CVL specimens [32-34]. This may have been due to differences in the methods of CVL collection employed, sampling frequency or the population characteristics in which these assays were utilized. It is also lower than estimates of HSV shedding reported in previous WIHS study by Augenbraun et al. [35]. However, direct comparison between this and the previous study may not be cogent as studies used differed selection criteria for enrolling participants as well as different specimen types and sampling strategies.

Despite this limitation, the study has several unique strengths. First, although HSV-2 shedding was measured at single time point, we used rich longitudinal clinical data accumulated by WIHS over many years to link our PCR results with the observed clinical course of GH in these women. Second, as many studies explore HSV-2 using frequent sampling such as daily or even multiple sampling in a day [36,37], these results point to potential feasibility of studies of HSV-2 natural history in the settings with a less frequent sampling schedule and collection of data.

In summary, single qPCR measurement of HSV DNA in CVL specimens among women with chronic HSV-2 infection can provide useful information for assessing genital herpes in the setting of infrequent sampling of specimens. Observed positive correlation of the presence and quantity of HSV-2 DNA with active symptomatic disease with frequent reactivations suggests that HSV-2 quantification could be a useful tool in evaluating HSV-2 infected patients with chronic genital herpes and may guide better antiviral therapy.

Acknowledgements

Data in this manuscript were collected by the Women's Interagency HIV Study (WIHS) Collaborative Study Group with centers (Principal Investigators) at New York City/Bronx Consortium (Kathryn Anastos); Brooklyn, NY (Howard Minkoff); Washington DC Metropolitan Consortium (Mary Young); The Connie Wofsy Study Consortium of Northern California (Ruth Greenblatt); Los Angeles County/Southern California Consortium (Alexandra Levine); Chicago Consortium (Mardge Cohen); Data Coordinating Center (Stephen Gange). The WIHS is funded by the National Institute of Allergy and Infectious Diseases (U01-AI-35004, U01-AI-31834, U01-AI-34994, U01-AI-34989, U01-AI-34993, and U01-AI-42590) and by the National Institute of Child Health and

Human Development (U01-HD-32632). The study is co-funded by the National Cancer Institute, the National Institute on Drug Abuse, and the National Institute on Deafness and Other Communication Disorders. Funding is also provided by the National Center for Research Resources (UCSF-CTSI Grant Number UL1 RR024131). The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health.

Author details

¹Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.

²Johns Hopkins University School of Medicine, Baltimore, MD, USA.

³Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. ⁴Albert Einstein College of Medicine, Bronx, NY, USA. ⁵Cook County Medical Center, Chicago, IL, USA. ⁶University of California, San Francisco School of Medicine, San Francisco, CA, USA. ⁷Georgetown University Medical Center, Washington, D. C., USA. ⁸Maimonides Medical Center and SUNY Downstate, Brooklyn, NY, USA. ⁹University of Southern California, Los Angeles, CA, USA.

Authors' contributions

BA, TCQ, SJG, CB, CAG conceived and designed the study. BA, AH, OL, CAG performed the assay design and experiments. BA, SJG, CC carried out statistical analysis. KA, MC, RMG, DJM, HM, MN, SJG contributed samples and data. BA wrote initial draft of the manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Received: 6 September 2010 Accepted: 18 November 2010

Published: 18 November 2010

References

1. Smith JS, Robinson NJ: Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review. *J Infect Dis* 2002, **186**(Suppl 1):S3-28.
2. Xu F, Sternberg MR, Kottiri BJ, McQuillan GM, Lee FK, Nahmias AJ, Berman SM, Markowitz LE: Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. *JAMA* 2006, **296**(8):964-973.
3. Mole L, Ripich S, Margolis D, Holodniy M: The impact of active herpes simplex virus infection on human immunodeficiency virus load. *J Infect Dis* 1997, **176**(3):766-770.
4. Schacker T, Zeh J, Hu H, Shaughnessy M, Corey L: Changes in plasma human immunodeficiency virus type 1 RNA associated with herpes simplex virus reactivation and suppression. *J Infect Dis* 2002, **186**(12):1718-1725.
5. Ashley RL: Sorting out the new HSV type specific antibody tests. *Sex Transm Infect* 2001, **77**(4):232-237.
6. Ashley RL, Wald A: Genital herpes: review of the epidemic and potential use of type-specific serology. *Clin Microbiol Rev* 1999, **12**(1):1-8.
7. Corey L, Adams HG, Brown ZA, Holmes KK: Genital herpes simplex virus infections: clinical manifestations, course, and complications. *Ann Intern Med* 1983, **98**(6):958-972.
8. Benedetti J, Corey L, Ashley R: Recurrence rates in genital herpes after symptomatic first-episode infection. *Ann Intern Med* 1994, **121**(11):847-854.
9. Filen F, Strand A, Allard A, Blomberg J, Herrmann B: Duplex real-time polymerase chain reaction assay for detection and quantification of herpes simplex virus type 1 and herpes simplex virus type 2 in genital and cutaneous lesions. *Sex Transm Dis* 2004, **31**(6):331-336.
10. Wald A, Huang ML, Carrell D, Selke S, Corey L: Polymerase chain reaction for detection of herpes simplex virus (HSV) DNA on mucosal surfaces: comparison with HSV isolation in cell culture. *J Infect Dis* 2003, **188**(9):1345-1351.
11. Hobson A, Wald A, Wright N, Corey L: Evaluation of a quantitative competitive PCR assay for measuring herpes simplex virus DNA content in genital tract secretions. *J Clin Microbiol* 1997, **35**(3):548-552.
12. van Doornum GJ, Guldemeester J, Osterhaus AD, Niesters HG: Diagnosing herpesvirus infections by real-time amplification and rapid culture. *J Clin Microbiol* 2003, **41**(2):576-580.
13. Cone RW, Hobson AC, Palmer J, Remington M, Corey L: Extended duration of herpes simplex virus DNA in genital lesions detected by the polymerase chain reaction. *J Infect Dis* 1991, **164**(4):757-760.

14. Cone RW, Hobson AC, Brown Z, Ashley R, Berry S, Winter C, Corey L: **Frequent detection of genital herpes simplex virus DNA by polymerase chain reaction among pregnant women.** *JAMA* 1994, **272**(10):792-796.
15. Slomka MJ, Emery L, Munday PE, Mouldsdaile M, Brown DW: **A comparison of PCR with virus isolation and direct antigen detection for diagnosis and typing of genital herpes.** *J Med Virol* 1998, **55**(2):177-183.
16. Safrin S, Shaw H, Bolan G, Cuan J, Chiang CS: **Comparison of virus culture and the polymerase chain reaction for diagnosis of mucocutaneous herpes simplex virus infection.** *Sex Transm Dis* 1997, **24**(3):176-180.
17. Fuchs J, Celum C, Wang J, Hughes J, Sanchez J, Cowan F, Reid S, Delany-Moretlwe S, Corey L, Wald A, HIV Prevention Trials Network 039 Protocol Team: **Clinical and virologic efficacy of herpes simplex virus type 2 suppression by acyclovir in a multicontinent clinical trial.** *J Infect Dis* 2010, **201**(8):1164-1168.
18. Gupta R, Wald A, Krantz E, Selke S, Warren T, Vargas-Cortes M, Miller G, Corey L: **Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract.** *J Infect Dis* 2004, **190**(8):1374-1381.
19. Koelle DM, Wald A: **Herpes simplex virus: the importance of asymptomatic shedding.** *J Antimicrob Chemother* 2000, **45**(Suppl T3):1-8.
20. Leone P, Warren T, Hamed K, Fife K, Wald A: **Famciclovir reduces viral mucosal shedding in HSV-seropositive persons.** *Sex Transm Dis* 2007, **34**(11):900-907.
21. Sacks SL, Griffiths PD, Corey L, Cohen C, Cunningham A, Dusheiko GM, Self S, Spruance S, Stanberry LR, Wald A, Whitley RJ: **Introduction: Is viral shedding a surrogate marker for transmission of genital herpes?** *Antiviral Res* 2004, **63**(Suppl 1):S3-9.
22. Wald A, Corey L, Cone R, Hobson A, Davis G, Zeh J: **Frequent genital herpes simplex virus 2 shedding in immunocompetent women. Effect of acyclovir treatment.** *J Clin Invest* 1997, **99**(5):1092-1097.
23. Tang JW, Lin M, Chiu L, Koay ES: **Viral loads of herpes simplex virus in clinical samples—a 5-year retrospective analysis.** *J Med Virol* 2010, **82**(11):1911-1916.
24. Mark KE, Wald A, Margaret AS, Selke S, Olin L, Huang ML, Corey L: **Rapidly cleared episodes of herpes simplex virus reactivation in immunocompetent adults.** *J Infect Dis* 2008, **198**(8):1141-1149.
25. Barkan SE, Melnick SL, Preston-Martin S, Weber K, Kalish LA, Miotti P, Young M, Greenblatt R, Sacks H, Feldman J: **The Women's Interagency HIV Study. WIHS Collaborative Study Group.** *Epidemiology* 1998, **9**(2):117-125.
26. Ameli N, Bacchetti P, Morrow RA, Hessel NA, Wilkin T, Young M, Cohen M, Minkoff H, Gange SJ, Greenblatt RM: **Herpes simplex virus infection in women in the WIHS: epidemiology and effect of antiretroviral therapy on clinical manifestations.** *AIDS* 2006, **20**(7):1051-1058.
27. Greenblatt RM, Bacchetti P, Barkan S, Augenbraun M, Silver S, Delapenha R, Garcia P, Mathur U, Miotti P, Burns D: **Lower genital tract infections among HIV-infected and high-risk uninfected women: findings of the Women's Interagency HIV Study (WIHS).** *Sex Transm Dis* 1999, **26**(3):143-151.
28. Corey L, Huang ML, Selke S, Wald A: **Differentiation of herpes simplex virus types 1 and 2 in clinical samples by a real-time taqman PCR assay.** *J Med Virol* 2005, **76**(3):350-355.
29. Namvar L, Olofsson S, Bergstrom T, Lindh M: **Detection and typing of Herpes Simplex virus (HSV) in mucocutaneous samples by TaqMan PCR targeting a gB segment homologous for HSV types 1 and 2.** *J Clin Microbiol* 2005, **43**(5):2058-2064.
30. Cox C: **Limits of quantification for laboratory assays.** *Appl Statist* 54:63-75.
31. Aumakhan B, Gaydos CA, Quinn TC, Beyrer C, Benning L, Minkoff H, Merenstein DJ, Cohen M, Greenblatt R, Nowicki M, Anastos K, Gange SJ: **Clinical reactivations of herpes simplex virus type 2 infection and human immunodeficiency virus disease progression markers.** *PLoS One* 2010, **5**(4):e9973.
32. Aryee EA, Bailey RL, Natividad-Sancho A, Kaye S, Holland MJ: **Detection, quantification and genotyping of Herpes Simplex Virus in cervicovaginal secretions by real-time PCR: a cross sectional survey [abstract].** *Virology* 2005, **2**:61.
33. Legoff J, Bouhhal H, Gresenguet G, Weiss H, Khonde N, Hocini H, Desire N, Si-Mohamed A, de Dieu Longo J, Chemin C, Frost E, Pepin J, Malkin JE, Mayaud P, Belec L: **Real-time PCR quantification of genital shedding of herpes simplex virus (HSV) and human immunodeficiency virus (HIV) in women coinfecting with HSV and HIV [abstract].** *J Clin Microbiol* 2006, **44**:423-432.
34. Nagot N, Foulongne V, Becquart P, Mayaud P, Konate I, Quedraogo A, Defer MC, Weiss H, Van de Perre P, Segondy M: **Longitudinal assessment of HIV-1 and HSV-2 shedding in the genital tract of West African women.** *J Acquir Immune Defic Syndr* 2005, **39**(5):632-634.
35. Augenbraun M, Corey L, Reichelderfer P, Wright DJ, Burns D, Koelle DM, Robison E, Cohen M, Women's Health Studies 002 Study Group: **Herpes simplex virus shedding and plasma human immunodeficiency virus RNA levels in coinfecting women.** *Clin Infect Dis* 2001, **33**(6):885-890.
36. Tata S, Johnston C, Huang ML, Selke S, Margaret A, Corey L, Wald A: **Overlapping reactivations of herpes simplex virus type 2 in the genital and perianal mucosa.** *J Infect Dis* 2010, **201**(4):499-504.
37. Mark KE, Wald A, Margaret AS, Selke S, Olin L, Huang ML, Corey L: **Rapidly cleared episodes of herpes simplex virus reactivation in immunocompetent adults.** *J Infect Dis* 2008, **198**(8):1141-1149.

doi:10.1186/1743-422X-7-328

Cite this article as: Aumakhan *et al.*: Genital herpes evaluation by quantitative TaqMan PCR: correlating single detection and quantity of HSV-2 DNA in cervicovaginal lavage fluids with cross-sectional and longitudinal clinical data. *Virology Journal* 2010 **7**:328.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

